CordenPharma, AGC, Vetter, Lonza Expand; LabVantage Adds Capabilities
The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, AGC Biologics, Vetter, Lonza, Rentschler Biopharma, and LabVantage.
Chemicals/Chemical API Manufacturing
CordenPharma Expands Peptide Mfg Capacity
CordenPharma has expanded peptide manufacturing capacity at its active pharmaceutical ingredient (API) facility, CordenPharma Colorado, in Boulder, Colorado.
CordenPharma Colorado recently completed expansion of its solid-phase peptide manufacturing capacity with the addition of a 3,000-L solid-phase-peptide-synthesis (SPPS) vessel, which provides the ability to manufacture a complex long peptide with a 400-kg output per single batch.
CordenPharma Colorado provides large-scale peptide manufacturing and has a 10,000 L-SPPS vessel and a 100-cm high-pressure reverse phase purification column. Purification of the final peptide is performed at scales in columns ranging from 5 cm to 100 cm.
Source: CordenPharma
Biologics Manufacturing
AGC Biologics Invests $1.1 M to Expand Center for Plasmid DNA
AGC Biologics, a contract biologics manufacturer, has invested EUR 1 million ($1.1 million) to expand its pDNA Center of Excellence in Heidelberg, Germany for process development and manufacturing of plasmid DNA (pDNA).
The investment in a laboratory build-out includes an increase of lab area, additional staffing, and equipment to support high-throughput techniques and quality-by-design processes.
Source: AGC Biologics
Formulation Development-Drug Product Manufacturing
Vetter Acquires Clinical Mfg Site; In Pact with Rentschler Biopharma
Vetter, a CDMO of aseptic filling and packaging, is expanding with the purchase of a clinical manufacturing site in Rankweil, Austria.
The production site was purchased along with its existing inventory, including a vial-filling line and a freeze dryer for liquid and lyophilized products as well as material preparation and laboratory equipment. Vetter says it plans to start operations at the site, Development Service Rankweil, in the second half of 2021.
In a separate development, Vetter and Rentschler Biopharma, a Laupheim, Germany-based biologics CDMO, have formed a strategic collaboration to offer combined service offerings. The collaboration will use Rentschler Biopharma’s experience in drug-substance manufacturing, including bioprocess development and active pharmaceutical ingredient production, and Vetter’s expertise in aseptic fill–finish and secondary packaging. Over the next months (as reported on July 6, 2020), pilot client projects with joint teams from both companies will be further validated.
Source: Vetter (expansion) Vetter (partnership) and Rentschler Biopharma
Lonza Establishes Dry-Powder Inhaler Center of Excellence
Lonza has established a Center of Excellence for dry-powder inhaler (DPI) drug-product development at its Bend, Oregon site.
The DPI services provide particle-engineering knowledge and capabilities at Lonza-Bend while incorporating Lonza’s site-network capabilities where applicable for specific customers and/or drug programs. The core service offer is comprised of an evaluation of particle-engineering approaches (spray drying and micronization) along with capsule-based DPI formulation design and development.
Source: Lonza
General
LabVantage Adds Increased Functionality to LIMS Platform
LabVantage Solutions, a laboratory informatics provider, has released the 8.5 edition of its LabVantage platform to provide an integrated Scientific Data Management System (SDMS) to provide security and control against data loss or modification. The optional SDMS interfaces with all elements of the LabVantage platform, including LIMS (laboratory information management system), ELN (electronic laboratory notebook), and LES (laboratory execution system).
LabVantage 8.5 also includes a new Configuration Management and Transfer feature for greater LIMS administration productivity and better control, along with a number of enhancements that make the LabVantage ELN easier to use, and that makes it easier to manage configuration changes to the LIMS and master data.
In addition, LabVantage 8.5 includes many additional advancements to the ELN, LES, biobanking, and other elements of the system to enhance overall ease of use and productivity.
Source: LabVantage
